Announcement • Jul 15
Ernexa Therapeutics Receives Independent Validation Of ERNA-101 With Complete Tumor Clearance And Durable Survival In Ovarian Cancer Models Ahead Of Planned Clinical Entry Ernexa Therapeutics announced compelling new preclinical data independently validating the anti-tumor activity of its lead cell therapy candidate, ERNA-101, in combination with PD-1 checkpoint inhibition. The independently conducted study successfully reproduced earlier findings generated at The University of Texas Anderson Cancer Center, demonstrating complete tumor clearance and durable long-term survival in a substantially larger study. The results further strengthen confidence in ERNA-101's mechanism of action and provide important third-party validation as the Company advances toward its planned Investigational New Drug (IND) submission in the third quarter of 2026 and anticipated first-in-human Phase 1 clinical trial in the fourth quarter. In the study, ERNA-101 combined with anti-PD-1 therapy achieved complete tumor clearance and long-term survival in 10 of 15 treated animals (67%). No complete tumor clearance or durable survival was observed in any of the remaining 45 animals treated with ERNA-101 alone, anti-PD-1 alone, or left untreated, demonstrating the unique anti-tumor activity of the combination therapy. Earlier studies performed by The University of Texas Anderson Cancer Center demonstrated that ERNA-101 selectively homes to ovarian tumors and delivers its engineered IL-7/IL-15 fusion cytokine directly into the tumor microenvironment. This localized immune activation increased infiltration of cancer-fighting T cells into tumors that typically evade immune detection, providing the biological rationale for combining ERNA-101 with PD-1 checkpoint inhibitors. The newly completed independent study reproduced those findings and further demonstrated that this strategy generates durable anti-tumor responses that were not achieved with either therapy alone. The study was conducted by an independent contract research organization using expanded treatment groups in an immunocompetent ID8luc-ova syngeneic ovarian cancer model. Tumor burden was monitored longitudinally through bioluminescence imaging to evaluate treatment response and confirm complete tumor clearance. The study included four treatment arms: ERNA-101 plus anti-PD-1, ERNA-101 monotherapy, Anti-PD-1 monotherapy, Untreated control. Complete tumor clearance and durable long-term survival were observed exclusively in the combination therapy group, further validating the synergistic mechanism between ERNA-101 and PD-1 blockade. With completion of this independent validation study, Ernexa remains on track to submit its IND application during the third quarter of 2026 and initiate its first-in-human Phase 1 clinical trial during the fourth quarter of 2026. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer. Announcement • Jun 18
Ernexa Therapeutics Positioned to Become A Clinical-Stage Biotechnology Company as ERNA-101 on Track for Planned Third Quarter 2026 IND Submission and First-In-Human Study Ernexa Therapeutics highlighted significant progress across manufacturing, regulatory and clinical development activities supporting ERNA-101, the Company's lead oncology candidate. With manufacturing process development completed, GMP production underway, IND-enabling activities advancing and an Investigational New Drug (IND) submission planned for the third quarter of 2026, Ernexa believes it is well-positioned to initiate its first-in-human Phase 1 clinical study in the fourth quarter of 2026 and transition into a clinical-stage biotechnology company. ERNA-101 is an engineered, allogeneic induced mesenchymal stem cell (iMSC) therapy derived from induced pluripotent stem cells (iPSCs) and designed to selectively home to tumors while delivering a proprietary IL-7/IL-15 fusion cytokine directly into the tumor microenvironment. The therapy is designed to address one of the most significant challenges in cancer treatment: immunologically "cold" tumors that evade immune recognition and often fail to respond to existing therapies. By activating T cells and natural killer (NK) cells while reshaping the local tumor environment, ERNA-101 is intended to enhance anti-tumor activity and potentially improve responses to checkpoint inhibitors. Ernexa recently achieved several key operational milestones supporting planned clinical entry, including: Completion of ERNA-101 manufacturing process development; Transition of ERNA-101 into GMP manufacturing for clinical supply production; Initiation of technology transfer activities to support future manufacturing scalability; Advancement of IND-enabling studies and regulatory documentation; Continued execution of clinical readiness activities for Phase 1 study initiation; Maintenance of timeline toward planned Third Quarter 2026 IND submission. These accomplishments build upon the successful completion of the Company's FDA Pre-IND meeting and support continued advancement toward regulatory submission and clinical evaluation. Preclinical studies evaluating ERNA-101 in combination with PD-1 blockade demonstrated: Complete elimination of detectable tumors; 100% long-term survival through study follow-up; Significant remodeling of the tumor microenvironment from immunosuppressive to immune-activated; Increased infiltration of CD4+ and CD8+ T cells; Enhanced T-cell persistence and anti-tumor activity; Reprogramming of tumor-associated macrophages into a tumor-fighting phenotype; Significant reductions in tumor burden and malignant ascites. Importantly, ERNA-101 demonstrated substantially greater anti-tumor activity when combined with PD-1 blockade compared to either treatment alone, supporting its potential as a complementary immunotherapy platform designed to enhance responses in difficult-to-treat solid tumors. Following the completion of a $10.5 million financing, Ernexa believes it has sufficient resources to execute its near-term development strategy and pursue several anticipated value-driving milestones over the next 12 to 18 months. Expected 2026 Milestones: Third Quarter of 2026: Release of first GMP clinical product batch; Completion of required IND-enabling studies; Submission of IND application for ERNA-101
Fourth Quarter of 2026: FDA review of IND application; Initiation of first-in-human Phase 1 clinical study; First patient enrollment in platinum-resistant ovarian cancer; Pre-IND meeting with FDA for ERNA-201 autoimmune disease program. Expected 2027 Milestones: First Half 2027: Initial clinical data from ERNA-101 Phase 1 study. Second Half 2027: Potential advancement into Phase 2 development; Potential strategic partnership opportunities; Potential expansion into additional solid tumor indications. New Risk • May 13
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$7.3m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$7.3m free cash flow). Share price has been highly volatile over the past 3 months (29% average weekly change). Earnings are forecast to decline by an average of 19% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (over 6x increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$21m net loss in 3 years). Market cap is less than US$100m (US$14.0m market cap). 
